Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Jan 14, 2013, 06:50 ET from Reportlinker

NEW YORK, Jan. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

http://www.reportlinker.com/p01081139/Liver-Cancer-Therapeutics-Market-to-2018---Nexavar-the-Only-Approved-Targeted-Therapy-for-Advanced-Disease-Continues-to-Dominate-as-Other-Late-Stage-Trials-Fail.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Summary Leading business intelligence provider, GBI Research, has released its latest research report, entitled: "Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail". The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

Scope

- Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018- Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan- Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns- Key drivers and barriers that affect the market- Coverage of pipeline molecules in various Phases of drug development- Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma- Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets

Reasons to buy

- Align your product portfolio to the markets with high growth potential- Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth- Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market- Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents 1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 - Introduction 9

3 Liver Cancer Therapeutics Market to 2018 - Overview 10

3.1 Introduction 10

3.1.1 Benign Tumor 10

3.1.2 Primary Liver Cancer 10

3.1.3 Secondary Liver Cancer 10

3.2 Symptoms 11

3.3 Diagnosis 11

3.3.1 Laboratory Tests 11

3.3.2 Imaging Tests 11

3.3.3 Others 12

3.4 Treatment Options 12

3.4.1 Surgery 13

3.4.2 Non-surgical 13

3.4.3 General Treatment Algorithm 15

3.4.4 Treatment by Stage 16

3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts 19

4.1 Revenue 19

4.2 Annual Cost of Therapy 22

4.3 Marketed Products 23

4.3.1 Nexavar 23

4.3.2 Miripla 25

4.4 Treatment Usage Pattern 27

4.4.1 Prevalence Population 28

4.4.2 Diagnosed Population 28

4.4.3 Prescription Population 28

4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28

4.5.1 Drivers 28

4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape 30

5.1 US 30

5.1.1 Introduction 30

5.1.2 Revenue 30

5.1.3 Cost of Therapy 32

5.1.4 Treatment Usage Pattern 33

5.2 Top Five European Countries 34

5.2.1 Introduction 34

5.2.2 Revenue 34

5.2.3 Cost of Therapy 36

5.2.4 Treatment Usage Pattern 37

5.3 Japan 38

5.3.1 Introduction 38

5.3.2 Revenue 38

5.3.3 Cost of Therapy 39

5.3.4 Treatment Usage Pattern 40

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis 41

6.1 Introduction 41

6.2 R&D Product Pipeline by Stage of Development 43

6.2.1 Phase III 43

6.2.2 Phase II/III 44

6.2.3 Phase II 44

6.2.4 Phase I/II 45

6.2.5 Phase I 46

6.2.6 Pre-Clinical 47

6.2.7 Discovery 47

6.3 Profiles of Promising Molecules 48

6.3.1 PrevOnco 48

6.3.2 Ramucirumab 48

6.3.3 ThermoDox 49

6.3.4 Afinitor 50

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape 51

7.1 Bayer 51

7.2 Dainippon Sumitomo Pharma 52

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations 53

8.1 Introduction 53

8.2 Deals by Geography 54

8.3 Deals by Year 55

8.4 Mergers and Acquisition Deals 56

8.4.1 Overview 56

8.4.2 Profiles of Major M&A Deals 57

8.5 Licensing Agreements 58

8.5.1 Overview 58

8.5.2 Profiles of Major Licensing Agreements 60

8.6 Co-Development Agreements 62

8.6.1 Overview 62

8.6.2 Profiles of Major Co-Development Agreements 63

9 Liver Cancer Therapeutics Market to 2018 - Appendix 64

9.1 Market Definitions 64

9.2 Abbreviations 64

9.3 Bibliography 66

9.4 Research Methodology 67

9.4.1 Coverage 67

9.4.2 Secondary Research 68

9.4.3 Primary Research 68

9.5 Therapeutic Landscape 69

9.5.2 Market Size by Geography 70

9.6 Geographical Landscape 71

9.7 Pipeline Analysis 71

9.8 Competitive Landscape 72

9.8.1 Expert Panel Validation 72

9.9 Contact Us 72

9.10 Disclaimer 72

List of TablesTable 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2011 27Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2011-2018 27Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2004-2011 33Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2011-2018 33Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2011 37Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2011-2018 37Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2004-2011 40Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2011-2018 40Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62List of FiguresFigure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2018 27Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2004-2018 33Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2018 37Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2004-2018 40Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55Figure 24: GBI Research Market Forecasting Model 71Companies MentionedBayerDainippon Sumitomo PharmaTo order this report:Therapy Industry: Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com